Clarify of Predictive Risk Factors of Chemotherapy-induced Liver Injury

Overview

The most common toxicity of TP (docetaxel and cisplatin) chemotherapy is chemotherapy-induced liver injury. However, patients don't always experience same chemotherapy-induced liver injury for the same drugs. Therefore, the investigators designed the present study to clarify risk factors associated with the development of severe hepatotoxicity after therapy with docetaxel and cisplatin for nasopharyngeal carcinoma (NPC).

Full Title of Study: “Clarify of Predictive Risk Factors of Chemotherapy-induced Liver Injury After Therapy With Docetaxel and Cisplatin for Nasopharyngeal Carcinoma”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Screening
    • Masking: None (Open Label)
  • Study Primary Completion Date: January 1, 2018

Detailed Description

Nasopharyngeal carcinoma (NPC) is one of the most common malignancies in southern China , with an annual incidence of 15 to 50 cases per 100,000 people. NPC is both radiosensitive and chemosensitive. Recently, many new drugs including docetaxel and cisplatin have been incorporated in the induction chemotherapy phase of NPC. The most common toxicity of TP (docetaxel and cisplatin) chemotherapy is chemotherapy-induced liver injury, and appropriate management of these toxicities can help patients improve tolerance for chemotherapy. However, patients don't always experience same chemotherapy-induced liver injury for the same drugs. Therefore, it is important to determine the risk factors to predict chemotherapy-induced liver injury. The investigators designed the present study to clarify risk factors associated with the development of severe hepatotoxicity after therapy with docetaxel and cisplatin for nasopharyngeal carcinoma (NPC).

Interventions

  • Drug: docetaxel and cisplatin
    • Patients receive TP (docetaxel and cisplatin) chemotherapy

Arms, Groups and Cohorts

  • Experimental: Study Population
    • Patients with advanced nasopharyngeal carcinoma scheduled to receive the first line, first cycle TP (docetaxel and cisplatin) chemotherapy

Clinical Trial Outcome Measures

Primary Measures

  • Relationship of white blood cell level and chemotherapy-induced liver injury
    • Time Frame: 3 weeks
    • White blood cell level (cells/L) and liver function (such as ALT, AST, ALP, and bilirubin levels) will be tested before (1-3 days) and after (21 ± 3 days) first cycle of chemotherapy, and the relationship of white cell level fluctuation and liver injury will be investigated.
  • Relationship of albumin level and chemotherapy-induced liver injury
    • Time Frame: 3 weeks
    • Albumin (g/L) and liver function (such as ALT, AST, ALP, and bilirubin levels) will be tested before (1-3 days) and after (21 ± 3 days) first cycle of chemotherapy, and the relationship of albumin fluctuation and liver injury will be investigated.
  • Relationship of hemoglobin level and chemotherapy-induced liver injury
    • Time Frame: 3 weeks
    • Hemoglobin (g/L) and liver function (such as ALT, AST, ALP, and bilirubin levels) will be tested before (1-3 days) and after (21 ± 3 days) first cycle of chemotherapy, and the relationship of hemoglobin fluctuation and liver injury will be investigated.
  • Relationship of blood platelet level and chemotherapy-induced liver injury
    • Time Frame: 3 weeks
    • Blood platelet (cells/L) and liver function (such as ALT, AST, ALP, and bilirubin levels) will be tested before (1-3 days) and after (21 ± 3 days) first cycle of chemotherapy, and the relationship of blood platelet fluctuation and liver injury will be investigated.

Secondary Measures

  • Relationship of age and chemotherapy-induced liver injury
    • Time Frame: 3 weeks
    • The age(years) will be recorded when the therapy starts. The liver function (such as ALT, AST, ALP, and bilirubin levels) will betested before (1-3 days) and after (21 ± 3 days) first cycle of chemotherapy. The relationship of age and liver injury will be investigated.
  • Relationship of height and chemotherapy-induced liver injury
    • Time Frame: 3 weeks
    • The height (kg) will be recorded when the therapy starts. The liver function (such as ALT, AST, ALP, and bilirubin levels) will betested before (1-3 days) and after (21 ± 3 days) first cycle of chemotherapy. The relationship of height and liver injury will be investigated.

Participating in This Clinical Trial

Inclusion Criteria

  • Patients with advanced nasopharyngeal carcinoma.
  • Patients scheduled to receive the first line, first cycle TP (docetaxel and cisplatin) chemotherapy.
  • Normal liver function biomarkers including ALT,AST,ALP,TBIL before recruitment.
  • Minimum age of 18 years.
  • Life expectancy at least 3 months.

Exclusion Criteria

  • Patients previously received chemotherapy
  • Patients who have liver metastases.
  • Patients who take other drugs that may affect liver function

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 70 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Second Affiliated Hospital of Nanchang University
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Long Huang, MD, Study Director, The Second Afiliated Hospital of Nanchang University
  • Overall Contact(s)
    • Long Huang, MD, 13699549060, huanglongdoctor@163.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.